Effect of Nigella sativa oil supplement on risk factors for cardiovascular diseases in patients with type 2 diabetes mellitus

Abstract

This study aimed to evaluate the effects of Nigella sativa oil on serum level of systemic inflammation, oxidative stress, fasting blood glucose (FBG), and lipid profile in patients with type 2 diabetes mellitus (T2DM). This double-blind randomized clinical trial study was based on 50 patients with T2DM. Patients were allocated randomly to either N. sativa oil or placebo groups. The intervention group received 1,000 mg N. sativa oil as two capsules, daily for 8 weeks, whereas the placebo group received a corresponding placebo. At baseline and the end of the study, 5 ml blood was collected from each patient after 14-hour fasting for measuring serum C-reactive protein (hs-CRP), malondialdehyde (MDA), FBS, and lipid profile. Analyses covariance was performed to compare investigated parameters between two groups, controlled for relevant covariates. Using N. sativa supplement was significantly associated with decrease in FBS (p < .001), triglyceride (p < .001), total cholesterol (p < .001), low-density lipoprotein cholesterol (p < .001), serum hs-CRP, MDA (p < .001) and increase in serum level of high-density lipoprotein cholesterol (p < .001) in intervention group compared with placebo group. Nigella sativa oil supplement has cardiovascular protective effects in patients with T2DM, by improving the lipid profile and glycemia, by reducing the C-reactive protein level and the lipid peroxidation.

Effects of Nigella sativa oil supplementation on selected metabolic parameters and anthropometric indices in patients with coronary artery disease: A randomized, double‐blind, placebo‐controlled clinical trial

“…Our results indicated no significant change in any lipid profile parame- et al, 2019). In other trials on NAFLD and diabetic patients, 1 g of NS oil for 8 weeks caused a significant reduction in TC, TG, LDL-C, and HDL-C improvement (Kooshki, Tofighiyan, Rastgoo, Rakhshani, & Miri, 2020;Rashidmayvan, Mohammadshahi, Seyedian, & Haghighizadeh, 2019). Nevertheless, a pilot study on healthy individuals showed no substantial effect of NS powder on lipid profile (Pelegrin et al, 2019).…”

Evaluation of the Anti-diabetic Activity and Lc-esi/ltqorbitrap/ms/ms Profiling of an Aqueous Extract of Pergularia Tomentosa L. Aerial Parts

“…By this way, 23 metabolites could be identi ed. In particular, the LC-MS analysis of P. tomentosa extract suggested the occurrence of cardenolides (4,8,(16)(17)21) duble-linked cardenolides (1-3, 5, 7, 12-15, 18-20, 22-23), and avone glycosides (6, 9-11) (Fig. 2 and Table 3).…”

“…Some issues, however, limit the effectiveness of these options, such as failure to hinder diabetic complications and prominent side effects [6,7]. WHO reported that 366 million people would be affected by type 2 diabetes mellitus until 2030 increasing the risk of morbidity and mortality due to cardiovascular disease [8]. Therefore, there is an increasing interest in investigating medicinal plants recognized in Traditional Medicine as a remedy to treat diabetes.…”

Black Cumin (Nigella sativa L.): A Comprehensive Review on Phytochemistry, Health Benefits, Molecular Pharmacology, and Safety

“…In a randomized clinical trial on patients with diabetic nephropathy accompanying chronic kidney disease, following NSO treatment, there was a significant reduction in blood glucose, serum creatinine, blood urea, and 24 h total urinary protein levels and an increase in glomerular filtration rate, 24 h total urinary volume, and hemoglobin level [ 140 ]. In a double-blind randomized clinical trial on T2D patients, NSO supplementation was accompanied by a lowering effect on lipid profile, glycemia, C-reactive protein level, and lipid peroxidation [ 141 ]. Complying with preclinical studies, a single-blind nonrandomized controlled clinical trial on T2D patients given with black cumin seed capsule demonstrated a significant decline in TC, LDL-C, TC/HDL-C, LDL-C/HDL-C ratios, DBP, MAP and HR, and increase of serum HDL-C level [ 142 ].…”